197 related articles for article (PubMed ID: 20516564)
1. Potential threat of drug-resistant and vaccine-escape HBV mutants to public health.
Teo CG; Locarnini SA
Antivir Ther; 2010; 15(3 Pt B):445-9. PubMed ID: 20516564
[TBL] [Abstract][Full Text] [Related]
2. Molecular genesis of drug-resistant and vaccine-escape HBV mutants.
Locarnini SA; Yuen L
Antivir Ther; 2010; 15(3 Pt B):451-61. PubMed ID: 20516565
[TBL] [Abstract][Full Text] [Related]
3. Drug-resistant and immune-escape HBV mutants in HIV-infected hosts.
Lacombe K; Boyd A; Gozlan J; Lavocat F; Girard PM; Zoulim F
Antivir Ther; 2010; 15(3 Pt B):493-7. PubMed ID: 20516570
[TBL] [Abstract][Full Text] [Related]
4. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy.
Yeh CT
Antivir Ther; 2010; 15(3 Pt B):471-5. PubMed ID: 20516567
[TBL] [Abstract][Full Text] [Related]
5. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
Locarnini S; Warner N
Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
[TBL] [Abstract][Full Text] [Related]
6. Antiviral drug-associated potential vaccine-escape hepatitis B virus mutants in Turkish patients with chronic hepatitis B.
Sayan M; Akhan SC
Int J Infect Dis; 2011 Oct; 15(10):e722-6. PubMed ID: 21784687
[TBL] [Abstract][Full Text] [Related]
7. Hepatitis B virus escape mutants induced by antiviral therapy.
Sheldon J; Soriano V
J Antimicrob Chemother; 2008 Apr; 61(4):766-8. PubMed ID: 18218641
[TBL] [Abstract][Full Text] [Related]
8. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
9. Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus.
Ohkawa K; Takehara T; Kato M; Deguchi M; Kagita M; Hikita H; Sasakawa A; Kohga K; Uemura A; Sakamori R; Yamaguchi S; Miyagi T; Ishida H; Tatsumi T; Hayashi N
J Infect Dis; 2008 Oct; 198(8):1150-8. PubMed ID: 18713056
[TBL] [Abstract][Full Text] [Related]
10. Prevalence and profile of mutations associated with lamivudine therapy in Indian patients with chronic hepatitis B in the surface and polymerase genes of hepatitis B virus.
Wakil SM; Kazim SN; Khan LA; Raisuddin S; Parvez MK; Guptan RC; Thakur V; Hasnain SE; Sarin SK
J Med Virol; 2002 Nov; 68(3):311-8. PubMed ID: 12226816
[TBL] [Abstract][Full Text] [Related]
11. Evidence of long-term suppression of hepatitis B virus DNA by tenofovir as rescue treatment in patients coinfected by HIV.
Quiros-Roldan E; Calabresi A; Lapadula G; Tirelli V; Costarelli S; Cologni G; Zaltron S; Puoti M; Carosi G; Torti C
Antivir Ther; 2008; 13(3):341-8. PubMed ID: 18572746
[TBL] [Abstract][Full Text] [Related]
12. Molecular analysis of an HBsAg-negative hepatitis B virus mutant selected in a tenofovir-treated HIV-hepatitis B virus co-infected patient.
Amini-Bavil-Olyaee S; Sheldon J; Lutz T; Trautwein C; Tacke F
AIDS; 2009 Jan; 23(2):268-72. PubMed ID: 19098499
[TBL] [Abstract][Full Text] [Related]
13. The clinical impact of early detection of the YMDD mutant on the outcomes of long-term lamivudine therapy in patients with chronic hepatitis B.
Paik YH; Han KH; Hong SP; Lee HW; Lee KS; Kim SO; Shin JE; Ahn SH; Chon CY; Moon YM
Antivir Ther; 2006; 11(4):447-55. PubMed ID: 16856618
[TBL] [Abstract][Full Text] [Related]
14. Hepatitis B virus genetic diversity.
Echevarría JM; Avellón A
J Med Virol; 2006; 78 Suppl 1():S36-42. PubMed ID: 16622876
[TBL] [Abstract][Full Text] [Related]
15. Coevolution and HBV drug resistance.
Khudyakov Y
Antivir Ther; 2010; 15(3 Pt B):505-15. PubMed ID: 20516572
[TBL] [Abstract][Full Text] [Related]
16. [HBV mutations during antiviral therapy in patients with chronic hepatitis B].
Hwang SG
Korean J Hepatol; 2005 Dec; 11(4):311-9. PubMed ID: 16380660
[No Abstract] [Full Text] [Related]
17. Infections by hepatitis B surface antigen gene mutants in Europe and North America.
Tabor E
J Med Virol; 2006; 78 Suppl 1():S43-7. PubMed ID: 16622882
[TBL] [Abstract][Full Text] [Related]
18. Effect of HIV co-infection on mutation patterns of HBV in patients with lamivudine-resistant chronic hepatitis B.
Iacomi F; Vincenti D; Vairo F; Solmone M; Mariano A; Piselli P; Puro V; Capobianchi MR; Antonucci G
J Med Virol; 2009 Jul; 81(7):1151-6. PubMed ID: 19475624
[TBL] [Abstract][Full Text] [Related]
19. HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance.
Schirmer P; Winters M; Holodniy M
J Clin Virol; 2011 Nov; 52(3):261-4. PubMed ID: 21840252
[TBL] [Abstract][Full Text] [Related]
20. Mutations associated with lamivudine-resistance in therapy-naïve hepatitis B virus (HBV) infected patients with and without HIV co-infection: implications for antiretroviral therapy in HBV and HIV co-infected South African patients.
Selabe SG; Lukhwareni A; Song E; Leeuw YG; Burnett RJ; Mphahlele MJ
J Med Virol; 2007 Nov; 79(11):1650-4. PubMed ID: 17854040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
